Clinical Trial Update: Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure [Phase 2]

View source ↗

Summary

Phase II add-on study evaluating vorinostat with azacitidine in higher-risk myelodysplastic syndrome patients after azacitidine failure; the trial was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Vorinostat (vorinostat)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2018-08-10